dbl cephalotin sodium 1g powder for injection vial
juno pharmaceuticals pty ltd - cefalotin sodium, quantity: 1.058 g (equivalent: cefalotin, qty 1 g) - injection, powder for - excipient ingredients: sodium bicarbonate - indications: cephalothin sodium for injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. culture and susceptibility studies should be performed. however, therapy may be instituted before results of susceptibility studies are obtained (see pharmacology: microbiology). respiratory tract: infections caused by s. pneumoniae, staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, klebsiella, and h. influenzae. skin and soft tissue: infections, including peritonitis, caused by staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, e.coli, pr. mirabilis and klebsiella. genitourinary tract: infections caused by e. coli, pr. mirabilis and klebsiella. septicaemia, including endocarditis: infections caused by s. pneumoniae, staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, s.
ledertrexate
wyeth (nz) ltd - methotrexate 2.5 mg/ml; - solution for injection - 2.5 mg/ml - active: methotrexate 2.5 mg/ml excipient: sodium chloride sodium hydroxide water for injection
ledertrexate
wyeth (nz) ltd - methotrexate 25 mg/ml; - solution for injection - 25 mg/ml - active: methotrexate 25 mg/ml excipient: sodium chloride sodium hydroxide water for injection
ledertrexate
wyeth (nz) ltd - methotrexate 2.5mg (as disodium salt); ; - tablet - 2.5 mg - active: methotrexate 2.5mg (as disodium salt) excipient: lactose monohydrate magnesium stearate sodium hydroxide starch
ledertrexate 2,5 mg tabl.
pfizer sa-nv - methotrexate disodium 2,74 mg - eq. methotrexate 2,5 mg - tablet - 2,5 mg - methotrexate 2.5 mg - methotrexate; l04ax03 methotrexate
ledertrexate 5 mg/2 ml inj. sol. i.m./i.v./i.ventricul./i.arter./i.thec. vial
pfizer sa-nv - methotrexate disodium 5,48 mg/2 ml - eq. methotrexate 5 mg/2 ml - solution for injection - 5 mg/2 ml - methotrexate 5 mg - methotrexate; l04ax03 methotrexate
ledertrexate 7,5 mg/ml inj. sol. i.v./i.m./i.arter./i.thec./i.ventricul./s.c. pre-filled syr.
pfizer sa-nv - methotrexate sodium 8,23 mg/ml - eq. methotrexate 7,5 mg/ml - solution for injection - 7,5 mg/ml - methotrexate sodium 8.23 mg/ml - methotrexate; l04ax03 methotrexate
ledertrexate 15 mg/2 ml inj. sol. i.thec./s.c./i.arter./i.ventricul./i.v./i.m. pre-filled syr.
pfizer sa-nv - methotrexate sodium 8,23 mg/ml - eq. methotrexate 7,5 mg/ml - solution for injection - 7,5 mg/ml - methotrexate sodium 8.23 mg/ml - methotrexate; l04ax03 methotrexate
ledertrexate concentrate 5000 mg/50 ml inj. sol. (conc.) i.thec./i.arter./i.ventricul./i.v./i.m. vial
pfizer sa-nv - methotrexate disodium 1096,8 mg/10 ml - eq. methotrexate 1000 mg/10 ml - concentrate for solution for injection - 100 mg/ml - methotrexate 100 mg - methotrexate; l04ax03 methotrexate
ledertrexate concentrate 1000 mg/10 ml inj. sol. (conc.) i.thec./i.arter./i.ventricul./i.v./i.m. vial
pfizer sa-nv - methotrexate disodium 1096,8 mg/10 ml - eq. methotrexate 1000 mg/10 ml - concentrate for solution for injection - 100 mg/ml - methotrexate 100 mg/ml - methotrexate; l04ax03 methotrexate